dsipar DREAM SPRAY DSIP – Montreal Peptides Canada

10.1097/00004647-199905000-00003 J

A counteraction with the stable gastric pentadecapeptide BPC 157 (PL 14736)

As MOTS-c activates AMPK and NRF2, it also indirectly suppresses the mTOR (mechanistic target of rapamycin) pathway, the master growth and anabolism regulator that, when chronically overactivated, accelerates the accumulation of senescent cells

FDA to Revisit BPC-157 and Other Peptides On July 2324, 2026, FDA's Pharmacy Compounding Advisory Committee will consider whether BPC-157, along with KPV, TB-500, MOTS-c, Semax, Epitalon, and Emideltide, should be included on the Section 503A Bulks List for pharmacy compounding

KLOW is the better tool for these cases

Store lyophilized vials at -20C, protected from light